Creative Biolabs provides a one-stop service for immune checkpoint assays.
Immune Checkpoint TargetsOur ServicesComparison of Checkpoint TechniquesApplicationsAdvancementRelevant ServicesResources
Immune checkpoints are a family of membrane proteins on the effector cells (such as T/B cells and NK cells) that consist of co-inhibitory and co-stimulatory pathways, enabling this cell group to remove unwanted substances while maintaining their tolerance
efficiently, an important pathway for immune regulation. Generally, there are two types of immune checkpoints: activating receptors and inhibitory receptors. Consequently, the general mechanisms between the immunotherapeutic antibodies can
be better described as a blockade pathway (functional antagonists) or enhance the pathway (functional agonists), as the receptors, blocking antibodies to them will have different properties and requirements for downstream signals. With years
of experience developing various biological assays, Creative Biolabs has initiated a novel set of cell-based assays to quantitatively and effectively assess the mechanism of action of the antibodies
by exploiting our cutting-edge technology and advanced knowledge in the field.
Immune Checkpoint Targets (including but not limited to):
Inhibitory Immune Checkpoints
Target
Receptor
B7-1 (CD80)
PD-L1
B7-2 (CD86)
CTLA4
PD-L1
PD-1
PD-L2
B7-1 & PD-1
CD48
CD244
CD155
TIGIT
CD112
CD112R
KIR
MHC I
NKG2D
RAE-1
Stimulatory Immune Checkpoints
MHC
TCR
B7-H2
ICOS
CD137L
CD137
OX40L
OX40
GITRL
GITR
CD70
CD27
CD40
CD40L
Details of Our Checkpoint Assays
We can help our clients design a roadmap that begins with the screening and analysis of the selected candidates, performs interaction analysis with the selected candidates, and then progresses to the analysis of the immunomodulatory function. Through
this roadmap, we can demonstrate the binding and functional properties of antibodies and their underlying mechanisms of action. We offer the following services:
Immunological checkpoint blocking assays from multiple classical pathways, readings by FACS or ELISA.
Custom cell-based, reporter, or receptor-ligand assay.
Induce biologically relevant responses without the use of difficult and expensive primary cells (reporter cell lines).
T cell proliferation assay, cytokine production assay, and T cell cytotoxicity assay.
All tests are performed using high-quality reagents and strictly controlled by experienced immunologists.
- High affinity and selectivity
- High sensitivity
- Suitable for diverse biological samples
- ELISA offers high specificity, widely used in research and clinical applications
Nucleic Acid Aptamer
- SELEX-based Aptamers
- High thermal stability
- Easy chemical synthesis/modification
- Low immunogenicity
- Specific target recognition without cell production
- Short oligonucleotides with specific binding to proteins
- Modifiable sequences
- Real-time molecular interaction monitoring
- High throughput and flexibility
Immune Checkpoint Assays Applications in Cancer Therapy
Immune Checkpoint Inhibitors (ICIs)
The efficacy of ICIs against PD-1, PD-L1, and CTLA-4 has moved cancer treatment from dismal histories of no improvement to exciting possibilities for cure by 'turning on' T cells and unleashing them to attack. ICIs, pioneered in melanoma, non-small
cell lung cancer, and renal cell carcinoma, have spread their wings to other cancers. Immune checkpoint assays provided by Creative Biolabs allow researchers or physicians to assess the functional activity of ICIs for their use in preclinical
as well as clinical studies.
Combination Therapies
Recently, to improve therapeutic outcomes of monotherapy with single-agent ICIs due to the limitations of incomplete responses and resistance, great efforts have been put into combination therapies with immunotherapies (such as ICIs), chemotherapies,
targeted therapies, or others, to boost the anti-tumor immune response. Creative Biolabs provides a variety of combination therapy checkpoint blockade assays, providing valuable information for guiding combination therapy screening and choosing
the optimum therapeutic regimen.
Clinical Efficacy and Challenges
However, despite their immense contributions to modern cancer therapy, ICIs will likely continue to face several challenges, such as resistance mechanisms and immune-related adverse events (irAEs). Creative Biolabs has been recasting a variety of
state-of-the-art assays intending to predict patient response to ICIs, to make the right treatment available to the right patients with minimal toxicity and side effects.
Advances in Immune Checkpoint Assay
Innovations in immune checkpoint assay technologies have opened new avenues for therapeutic interventions. Companies like Creative Biolabs are at the forefront of these advancements, contributing to the development of next-generation therapies.
New Checkpoint Discoveries
Emerging immune checkpoints such as CD3L1 and GPR34 are expanding the range of potential therapeutic targets. These novel checkpoints offer alternative pathways for immune regulation, particularly in cancers that do not respond to traditional
PD-1 or CTLA-4 inhibitors. Creative Biolabs is actively involved in developing assays to study these new targets, enhancing our understanding of their roles in immune modulation.
Dual and Bispecific Antibodies
Dual and bispecific antibodies represent a promising novel strategy of cancer immunotherapy, aimed at concurrently targeting two immune checkpoints that could boost therapeutic efficacy and lower resistance, and Creative Biolabs has established
innovative assays to evaluate the efficacy of dual and bispecific antibodies.
For more details, please feel free to contact us us or send us a query directly
Download our brochure